Sulzer Medica gets rights to bone tissue product
This article was originally published in Clinica
Swiss company Sulzer Medica is to strengthen its spinal portfolio through a marketing and distribution agreement with Tutogen Medical for its Tutoplast human bone tissue products for spinal applications. Sulzer will pay $3 million over two years for the rights to the products, which address the $1 billion spinal fusion market. The two companies will also collaborate on the development of a range of proprietary tissue products and implants.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.